Industry perspective: is biotech bouncing back?
After a challenging few years, momentum is building in the biotech industry as the market rebounds, but what could this mean for founders? Here, Geoffrey Hsu, General Partner at investment firm OrbiMed (NY, USA) and Portfolio Manager at the Biotech Growth Trust, a UK-listed biotech investment trust, discusses the recent trend shift in the biotech market and provides his suggestions for biotech companies looking for investment or to position themselves for purchase. Plotting the fall and rise after the COVID-19 biotech boom Between early 2021 and mid-2025, small-cap biotech stocks fell by 47.1% (GBP), even as the S&P 500 rose...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
